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ABSTRACT  
Background: Long-term clinical outcomes after HCV treatment of HIV/HCV patients are not well 
described. We aimed to compare the risk of all-cause and liver-related death according to HCV treatment 
response in HIV/HCV patients in the multi-cohort study COHERE. 
Methods: All patients who had started PEG-interferon + ribavirin (baseline) and followed for ≥72 weeks 
after baseline were included. Patients were categorized into three response groups depending on treatment 
duration and HCV-RNA measured in the window 24-72 weeks after baseline. Patients who received ≥24 
weeks of therapy were defined as responders if their last HCV-RNA measured between 24-72 weeks after 
baseline was negative, and having "unknown response" if HCV-RNA was unknown. Non-responders 
were treated for less than 24 weeks or were HCV-RNA+ between 24-72 weeks after baseline.  
Mortality rates were compared using survival analysis, and Cox regression used to compare hazard ratios 
of death between response groups. 
Results: 3,755 patients were included: 1031 (27.5%) responders, 1,639 (43.6%) non-responders and 1085 
(28.9%) with unknown response. Rates (per 1,000 PYFU, 95% CI) of all-cause death were 17.59 (14.88-
20.78), 10.43 (7.62-14.28) and 11.00 (8.54-14.23) for non-responders, responders and unknown 
responders, respectively. After adjustment, the relative hazard (non-responders vs. responders) for all-
cause death, liver-related death and non-liver-related death was 1.53 (95% CI 1.06-2.22), 3.39 (95% CI 
1.32-8.75) and 1.22 (95% CI 0.80-1.84), respectively. 
Conclusion: HIV/HCV patients with a favourable virological response to PEG-interferon + ribavirin had 
reduced risk of all-cause and liver-related death, while there was no difference in risk of non-liver-related 
death when comparing responders and non-responders. 
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Introduction 
Treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV) has until recently been the 
standard of care for treatment of HCV infection. Patients who achieve a sustained virologic 
response (SVR) i.e. they remain HCV-RNA negative 6 months after end of HCV treatment, are 
considered virologically cured. An SVR has been shown to halt or reverse progression of liver 
fibrosis [1, 2], but due to the slow evolution of liver disease in most patients, the clinical benefit 
of an SVR in terms of lower risk of liver-related complications and death, may take several years 
to manifest. During that period competing risk of death and risk of HCV re-infection could off-
set some of the benefit of HCV therapy [3]. Furthermore, due to the numerous adverse effects 
and contraindications to IFN-based therapy, particularly in HIV positive persons, HCV treatment 
was often not offered to those most in need of treatment [4]. Hence an evaluation of the clinical 
benefit of HCV treatment requires a large study population and long term follow up. 
In studies of HCV mono-infected patients, it has been shown that achieving an SVR is associated 
with a lower risk of liver-related [5-8] and all-cause mortality [6, 7]. The benefit is most 
pronounced for hepatic failure, and less so for risk of hepatocellular carcinoma (HCC).  
In HIV/HCV co-infected people the long-term clinical outcome of HCV treatment has not been 
evaluated in prospective studies of unselected patients. In a mixed retrospective-prospective 
study from Spain, Berenguer et al found that non-responders to HCV treatment had an almost 
nine-fold increased risk of liver-related clinical events compared with patients who achieved an 
SVR [9]. Two subsequent studies from the same group found that co-infected patients who 
achieved an SVR also had a reduced risk of HIV progression and non-liver-related death [10] 
and risk of all-cause mortality and liver-related events among patients with METAVIR ≤F2 
fibrosis at the time of treatment initiation [11].  
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
   
Compared with HCV mono-infected patients, the benefit of HCV treatment could theoretically 
be either greater due to accelerated fibrosis progression in co-infected patients, or lower due to 
differences in the prevalence of competing risk factors (both HIV-related and lifestyle factors) 
for mortality. 
The objectives of our study were to compare the long-term risk of all-cause mortality and liver-
related death according to response to PEG-IFN/RBV in HIV/HCV co-infected people enrolled 
in the large prospective multi-cohort study COHERE. 
 
Methods 
Patients 
The Collaboration of Observational HIV Epidemiological Research in Europe (COHERE, 
http://www.cohere.org) COHERE is a collaboration of 33 cohorts from across Europe and is part 
of the EuroCoord network (www.EuroCoord.net). COHERE was established in 2005 with the 
aim of conducting epidemiological research on the prognosis and outcome of HIV positive 
persons, which the individual contributing cohorts cannot address themselves because of sample 
size or heterogeneity of specific subgroups of HIV-positive persons. Each cohort submits data 
using the standardized HIV Collaboration Data Exchange Protocol (HICDEP) including 
information on patient demographics, HBV and HCV status and treatment, CD4 counts, use of 
cART, AIDS, and deaths. Eighteen European cohorts provided data for the present analysis. Our 
analyses were based on data merged in July 2013. 
 
All HCV infected patients in COHERE who had ever started PEG-IFN/RBV and who were 
followed-up for at least 72 weeks after treatment initiation were included. Baseline is defined as 
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the date of HCV treatment initiation, while time T0 is the date 72 weeks after treatment 
initiation.  During most of the study period, 48 weeks of HCV treatment was standard of care for 
co-infected patients. The earliest time point at which SVR24 can be assessed would be 72 weeks 
after treatment initiation for most patients. 
 
Definitions of HCV treatment response 
Follow up HCV-RNA values were not reported for all patients after end of therapy. We therefore 
categorized patients into three different HCV treatment response groups depending on HCV 
treatment duration and HCV-RNA results measured in the window 24-72 weeks after baseline. 
Patients who received at least 24 weeks of IFN/RBV were defined as “responders” if their latest 
HCV-RNA measured in the window 24-72 weeks after baseline was negative, and having 
“unknown response” if they had no HCV-RNA measured in the week 24-72 window. Patients 
were defined as “non-responders” if they had received less than 24 weeks of HCV therapy or if 
their latest HCV-RNA measured the week 24-72 window after baseline was positive. To define 
positive HCV-RNA values both qualitative (+/-) and quantitative measures (>615 IU/mL) were 
used. 
 
Biomarkers of fibrosis 
Levels of fibrosis were determined in the time window [-6;0] months prior to initiation of HCV 
treatment by measurement of the aspartate aminotransferase-to-platelet ratio index (APRI) [100 
 (aspartate aminotransferase /upper limit of normal)/ platelet count (109/l)]. Significant fibrosis 
(≥F2 on the METAVIR scale) and cirrhosis were defined as APRI >1.5 and APRI >2.0, 
respectively [12]. 
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Statistical methods 
Main characteristics of the patients are described and compared according to whether a person 
was classified as responder, non-responder or unknown response using Chi-square or non-
parametric Kruskal-Wallis tests as appropriate.  
Three different endpoints were analysed: all-cause mortality, liver-related death (LRD) and non-
liver related death. Causes of death were adjudicated individually by the participating cohorts in 
COHERE. Incidence rates were calculated as number of deaths divided by person-years of 
follow-up (PYFU) at risk. Confidence intervals around these estimates were calculated assuming 
a Poisson distribution. Mortality rates in the three groups were compared using standard survival 
analysis. Survival times accrued from the time T0 up to the date of death or last available follow-
up. In the analysis of time to cause-specific death people who died for other reasons were 
censored administratively at the date of last follow-up according to a competing-risk approach to 
analysis. People who died between baseline and T0 were excluded. Kaplan-Meier plots have 
been used to compare the cumulative risk of survival in the three exposure groups (responders, 
non-responders and unknown response to IFN/RBV). Univariable and multivariable Cox 
regression models were used to compare hazard ratios of death between these groups after 
controlling for a number of pre-specified confounders. We used a manual build-up of the 
multivariable models adjusting sequentially for subset of time-fixed confounders measured at the 
time of IFN/RBV initiation and grouped according to common features (e.g. demographics, 
HIV-related factors and HCV-related factors). We only included in these sets of potential 
confounders factors that have been previously described to be a common cause of treatment 
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initiation and risk of death, i.e. age, gender, origin, year of baseline, mode of HIV transmission, 
prior AIDS, current CD4 count, CD4 nadir, HIV RNA, HIV treatment at T0, HBsAg and APRI.   
 
Results 
Baseline characteristics 
We included a total of 3,755 patients, who had started HCV treatment and had at least 72 weeks 
of follow up after treatment was started (figure 1). Fifty-two patients had died between the date 
of HCV treatment start and week 72 (T0) of follow up. Median (IQR) duration PEG-IFN/RBV 
treatment was 9 (5 – 12) months. Among included patients, 1031 (27.5%) were responders, 1639 
(43.6%) non-responders and 1085 (28.9%) had unknown HCV treatment response. Compared 
with non-responders, responders started HCV treatment later (2007 vs. 2005), were more likely 
to be MSM (31% vs. 12%) and HBsAg positive (4.5% vs. 2.6%), had higher CD4 cell count (455 
vs. 405 cells/mm3), lower HCV-RNA levels (5.85 vs. 6.03 log10 IU/mL) and less likely to be 
female (20% vs. 25%) and have a prior AIDS diagnosis (22% vs. 27%). The median APRI score 
was slightly higher among responders (0.9 vs. 0.8 (table 1). Among patients with available data, 
the prevalence of cirrhosis, defined as APRI>2.0, was 16.0% in those with unknown response 
(104/650), 20.0% in non-responders (200/999) and 26.7% in responders (182/681). There were 
no differences between the response groups in time from baseline to assessment of APRI.  
 
All-cause mortality according to HCV treatment response 
After a median of 4.0 (IQR 2.0-6.5) years of follow up from T0, a total of 236 deaths had 
occurred. One hundred and thirty-eight (8.4%) of HCV treatment non-responders had died vs. 39 
(3.8%) deaths among responders and 59 (5.4%) with unknown HCV treatment response. The 
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rates (per 1,000 PYFU, 95% CI) of all cause death were 17.59 (14.88 – 20.78), 10.43 (7.62 – 
14.28) and 11.0 (8.54 – 14.23) for non-responders, responders and unknown responders, 
respectively. 
Figure 2 shows a Kaplan-Meier plot of the cumulative risk of all-cause mortality. For non-
responders the 7-year risk (95% CI) of all-cause death was 11.6% (9.5 - 13.7), while the 7-year 
risk was significantly lower for responders 8.0% (5.1 - 10.8) and for patients with unknown 
treatment response 7.8% (5.6 – 10.1). 
In the unadjusted Cox regression analysis, non-responders had a relative hazard of 1.64 (95% CI 
1.15 - 2.34) for all-cause death compared with responders. Results were similar after adjusting 
for demographics, HIV related (prior AIDS, on cART at T0 and current HIV-RNA and CD4+ 
cell count) and hepatitis related factors (HBsAg and APRI) in separate models (Figure 3). In the 
fully adjusted analysis, the relative hazard (non-responders vs. responders) for all cause death 
was 1.53 (95% CI 1.06 - 2.22). In all analyses, the relative hazard for all-cause death was not 
significant when comparing responders with unknown responders.  
 
Liver-related mortality according to HCV treatment response 
Liver-related death accounted for a third of all deaths among non-responders 48/138 (34.8%), 
but only 12.8% (5/39) among responders and 22.0% (13/59) among patients with unknown 
response. The rates (per 1000 PYFU, 95% CI) of liver-related death were 6.12 (4.61 – 8.12), 
1.34 (0.56 – 3.21) and 2.40 (1.41 – 4.18) for non-responders, responders and unknown 
responders, respectively. 
Among the five responders who died from LRD, two had a baseline APRI score indicating 
cirrhosis, one had significant fibrosis, and two had no information about fibrosis level. One 
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patient had evidence of HCV re-infection, while the four other remained HCV-RNA negative 
during follow up. None were diagnosed with hepatocellular carcinoma. 
The differences in risk of liver-related death between responders and non-responders were more 
pronounced than for all-cause death, but the confidence intervals were quite wide reflecting the 
relative low number of liver-related deaths in each group. The 7-year cumulative risk of liver-
related death was significantly higher for non-responders (4.2%, 95% CI 2.9 - 5.5) compared 
with the risk for responders (1.6%, 95% CI 0.0 – 3.3) and for patients with unknown treatment 
response (1.4%, 95% CI 0.4 - 2.4) (Figure 4). 
In the unadjusted Cox regression analysis, non-responders had a 4.43 (95% CI 1.76 – 11.14) 
increased risk of liver-related death compared with responders. Again, when adjusting for 
demographic, HIV related and hepatitis related factors there was little change in the incidence 
rate ratios (Figure 5). In the fully adjusted analysis, the relative hazard (non-responders vs. 
responders) of liver-related death was 3.39 (95% CI 1.32 – 8.75).  
 
Non-liver-related mortality according to HCV treatment response 
A total of 34 and 90 non-liver-related deaths occurred among responders and non-responders, 
respectively. In both groups non-HCC malignancy was the predominant cause of death (5/34 and 
16/90, respectively) followed by “unknown cause” (5/34 and 16/90, respectively). Four non-
responders died from AIDS, while there were no AIDS-related deaths in the responder group. To 
investigate whether a positive HCV treatment outcome also results in a lower risk of non-hepatic 
mortality, we repeated the analyses excluding all liver-related deaths. In the unadjusted analysis 
there was no difference (non-responders vs. responders) in incidence of non-liver-related death 
(hazard ratio 1.23, 95% CI 0.83 – 1.83).  Results were similar after adjustment for demographic 
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factors (1.19, 95% CI 0.79 – 1.78), HIV related factors (1.22, 95% CI 0.81 -1.82) and APRI and 
HBsAg status (1.35, 95% CI 0.91 -2.01). In the fully adjusted model the relative hazard was 
(1.22, 95% CI 0.80 – 1.84). Similarly, there was no difference when comparing responders with 
patients with unknown response (results not shown).  
 
Discussion 
In this large prospective study we included 3,755 HIV/HCV co-infected patients, who had 
received PEG-IFN/RBV. After a median of 4.0 years follow up from week 72 after treatment 
initiation, we found that patients who had a favorable treatment response had a significantly 
improved all-cause and liver-related mortality compared with patients who were non-responders. 
Our findings confirm the survival benefit of an SVR, shown in previous studies of HCV mono-
infected [6, 7] and HIV/HCV co-infected patients [9, 13]. However, compared with these studies 
the improved survival in our study was relatively modest (hazard ratio 1.53 for comparing 
responders with non-responders). In the Spanish study by Berenguer et al [9], which is the only 
other large observational study to include HIV/HCV co-infected patients from routine clinical 
practice, the incidence of all-cause mortality among patients with SVR was lower compared with 
the incidence among responders in our study (0.46 vs. 1.04 per 100 PYFU), whereas the all-
cause mortality was higher among non-responders in their study (3.12 vs. 1.76 per 100 PYFU). 
The excess all-cause mortality among non-responders in the Spanish study, seems to be mainly 
explained by a high prevalence (39%) of patients with advanced fibrosis or cirrhosis, resulting in 
a high incidence of liver-related death among non-responders compared to the incidence among 
non-responders observed in our study (1.65 vs. 0.61 per 100 PYFU). 
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In our study, only five out of 37 deaths in the treatment response group were from liver-related 
causes, and none of them due to HCC. Two of the five patients had evidence of cirrhosis at the 
time of treatment initiation, while one had evidence of HCV re-infection. Other studies have 
documented, that although an SVR reduces the risk, liver-related complications can occur several 
years after SVR. This is particularly the case with HCC in patients with cirrhosis at the time of 
treatment [14, 15]. Longer follow-up of our cohort is warranted to determine whether the 
incidence of HCC and other liver-related clinical events remains low for patients with treatment 
response.  
 
Since interferon is contra-indicated in patients with advanced cirrhosis due to the risk of liver 
decompensation, it is likely that patients with more advanced liver disease, who would have 
gained more clinical benefits from HCV eradication, were excluded. It is therefore conceivable 
that with the new tolerable and effective interferon-free direct-acting antivirals we will be able to 
prevent more liver- and, possibly, non-liver related complications, and this should be addressed 
in further observations. Although IFN-based therapy is no longer standard of care, the data 
presented in this paper are still of relevance to inform the prognosis for the many patients who 
were treated and cured with IFN before the arrival of DAA. Furthermore, IFN-based therapy is 
still commonly used in some countries that cannot afford the market price of DAA. In addition, 
consequences of cure are likely to be similar regardless of which treatment was used to achieve 
success. 
The link between chronic HCV infection and different autoimmune and lymphoproliferative 
conditions, e.g. mixed cryoglobulinaemia and some types of lymphoma, is well established [16]. 
There is also emerging evidence of an association between HCV infection and risk of 
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cardiovascular disease and other extra-hepatic diseases [16-18]. If the association is causal, one 
would expect a decrease in risk of non-liver-related death after SVR. In our study, we did not 
find a lower risk of non-liver-related death among those with a favorable HCV treatment 
response. This is in contrast to a national Spanish study that found a three-fold lower risk of non-
liver-related death in HIV/HCV co-infected patients with SVR compared with patients who did 
not achieve an SVR [10]. The reason for this difference is not clear, but with only five and 32 
non-liver-related deaths among patients with and without SVR, respectively, that study had 
limited power to investigate the question. It is possible that some of the apparent extra-hepatic 
health benefit of an SVR is related to behavioural differences after treatment and not the 
treatment outcome per se, as demonstrated by a Scottish observational study of HCV mono-
infected patients where patients who achieved SVR after IFN-based therapy had lower risk of 
hospitalization for alcohol intoxication and violence-related injury after treatment compared with 
non-responders to HCV treatment [19].  These findings should be explored in other cohorts and 
in patients undergoing DAA therapy. 
 
The major strengths of this analysis are the large number of co-infected patients recruited from a 
diverse geographical area throughout Europe, the long prospective follow up after HCV 
treatment and our ability to adjust for relevant risk factors for all-cause and LRD. However, like 
in all observational studies, there remains the possibility of unmeasured confounding. Another 
limitation is the lack of follow-up HCV-RNA measurements on all patients at least six months 
after end of therapy. In addition, some of the patients categorized as responders could have had 
HCV-RNA relapse, and some patients categorized as non-responders could have achieved an 
SVR. However, this limitation would only tend to underestimate the survival benefit of HCV 
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therapy. Unexpectedly, the prevalence of cirrhosis, as determined by the APRI score, was higher 
among responders than among non-responders. Data to calculate the APRI score were only 
available for 66% and 61% of responders and non-responders, respectively. If the reason for not 
having an APRI score is associated to disease status selection bias could have been introduced. 
 
In conclusion, we have shown that among HIV/HCV co-infected patients, a favourable 
virological response to HCV treatment is associated with reduced risk of both liver-related death 
and improved overall survival in the IFN era. Whether this holds true with the new direct-acting 
antivirals remains to be investigated. 
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Figure legends: 
Figure 1: Selection of patients 
Figure 2: Cumulative risk of all-cause mortality in the three HCV treatment response groups 
Figure 3: Adjusted hazard ratio for all-cause mortality according to HCV treatment response. 
Adjustments were made for pre-specified demographic-, HIV- and hepatitis-related 
factors in three separate Cox regression models as well as for all factors combined. 
Figure 4: The figure shows the cumulative risk of liver-related death in the three HCV treatment 
response groups 
Figure 5: The figure shows the adjusted hazard ratio for liver-related death according to HCV 
treatment response. Adjustments were made for pre-specified demographic-, HIV- and hepatitis-
related factors in three separate Cox regression models as well as for all factors combined. 
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Table 1. Patient characteristics at the date of HCV treatment initiation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MSM: men who have sex with men; ART: antiretroviral therapy; HBsAg: hepatitis B surface antigen; ALT: alanine aminotransferase; AST: aspartate 
aminotransferase; APRI: AST to platelet ratio index 
 
*N with data: 1437 
#N with data= 2653 
** N with data=2330 
 
Characteristics 
Responders 
N= 1031 
Non‐responders
N= 1639 
Unknown 
response 
N= 1085 
p‐value* 
Total 
N= 3755 
Age, median years (IQR)  42 (37, 46) 42 (37, 46) 41 (37, 46) 0.672  42 (37, 46)
Female, n (%)  210 (20.4%) 401 (24.5%) 245 (22.6%) 0.048  856 (22.8%)
Year of treatment initiation, median (IQR)  2007 (2005, 
2009) 
2005 (2003, 
2008) 
2005 (2003, 
2008)  <.001 
2006 (2003, 
2008) 
Region of birth, n (%)  0.002 
Europe  789 (83.2%) 1328 (87.8%) 820 (82.6%) 2937 (85.1%)
Other  83 (8.1%) 127 (7.7%) 92 (16.1%) 302 (8.0%)
Unknown  159 (16.8%) 184 (12.2%) 173 (17.4%) 516 (14.9%)
Mode of HIV transmission, n (%)  <.001 
MSM  322 (31.2%) 211 (12.9%)  130 (12.0%)  663 (17.7%) 
Heterosexual contact  133 (12.9%) 216 (13.2%)  169 (15.6%)  518 (13.8%) 
Injecting drug use  467 (45.3%)  1049 (64.0%)  693 (63.9%)  2209 (58.8%) 
Other/unknown  109 (10.6%)  163 (9.9%)  93 (8.6%)  365 (9.7%) 
Prior AIDS diagnosis, n (%)  226 (21.9%)  443 (27.0%)  254 (23.4%)  <.001  923 (24.6%) 
On ART, n (%)   864 (83.8%)  1429 (87.2%)  927 (85.4%)  0.048  3220 (85.8%) 
CD4 count,  median (IQR) cells/mm3  455 (180, 656) 405 (170, 582)  447 (248, 627)  <.001  423 (200, 619) 
HIV‐RNA, median (IQR) log10 cp/mL  3.01 (1.96, 4.34) 3.04 (1.72, 4.14) 2.97 (1.90, 4.13) 0.383  3.01 (1.84, 4.17)
HCV RNA, median (IQR) log10 IU/mL   5.85 (5.11, 6.34) 6.03 (5.51, 6.60) 5.98 (5.53, 6.51) <.001  5.95 (5.35, 6.51)
HCV genotype 1, n (%)*  274 (26.6%)  371 (22.6%)  158 (14.6%)  <.001  803 (21.4%) 
HBsAg‐positive, n (%)#  46 (3.8%)  42 (5.4%)  29 (4.2%)  <.001  117 (4.4%) 
Haemoglobin, median (IQR) g/dL  15 (12, 16)  15 (13, 16)  15 (14, 16)  0.046  15 (13, 16) 
Platelet count, median (IQR) 109/L  168 (123, 216)  171 (124, 221)  178 (131, 229)  0.006  173 (126, 222) 
ALT, median (IQR) IU/L  95 (51, 164)  71 (44, 121)  71 (44, 112)  <.001  71 (44, 112) 
AST, median (IQR)  IU/L  65 (41, 122)  59 (39, 95)  55 (37, 85)  <.001  60 (39, 100) 
APRI score, median (IQR)**  0.9 (0.5, 2.2)  0.8 (0.5, 1.7)  0.8 (0.5, 1.4)  <.001  0.8 (0.5, 1.7) 
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